This sequence of events includes release of synaptic glutamate and activation of neuronal glutamate receptors [15-18], the production of reactive oxygen species [19,20], accumulation of intracellular zinc[21], activation of poly(ADP-ribose) polymerase-1 [5,22], and mitochondrial permeability transition [23-25]. young (+)-Clopidogrel hydrogen sulfate (Plavix) rats that were rendered diabetic by streptozotocin (STZ, 50mg/kg, i.p.) injection. One week after STZ injection, rats were subjected to moderate hypoglycemia by insulin injection (10U/kg, i.p.) without anesthesia for five consecutive days. Pyruvate (500mg/kg) was given by intraperitoneal injection after each R/M hypoglycemia. Three hours after last R/M hypoglycemia, zinc accumulation was evaluated. Three days after R/M hypoglycemia, neuronal death, oxidative stress, microglial activation and GSH concentrations in the cerebral cortex were analyzed. Sparse neuronal death was observed in the cortex. Zinc accumulation, oxidative injury, microglial activation and GSH loss in the cortex after R/M hypoglycemia were all reduced by pyruvate injection. These findings suggest that when delivered alongside glucose, pyruvate may significantly improve the outcome after R/M hypoglycemia by circumventing a sustained impairment in neuronal glucose utilization resulting from PARP-1 activation. == Introduction == In an effort to use regular insulin injections to maintain blood glucose levels within a normal range, patients with type 1 diabetes are continuously at risk of encountering episodes of recurrent/moderate hypoglycemia [1,2]. In fact, the risk of hypoglycemia is the major factor limiting strict management of blood glucose. Animal studies have demonstrated that wide-spread neuronal death does not occur in the hippocampus unless blood glucose concentration falls below 1 mM or electroencephalographic (EEG) activity remains isoelectric (silent) for at least 10 minutes. However, it is still possible to induce scattered neuronal death in the cerebral cortex when blood glucose concentrations are sustained just above 1 mM [3-6]. Recurrent episodes of moderate hypoglycemia have been linked to decreased perception of the hypoglycemic state and blunted secretion of counter regulatory hormones, phenomena termed ‘hypoglycemia unawareness’ and ‘hypoglycemia-associated autonomic failure’ (HAAF), respectively [7-9]. Even moderate hypoglycemia may produce a significant increase in low-frequency EEG activity [10] and impair cognitive function [11] in diabetic patients. Moderate hypoglycemia, defined as low blood glucose levels (below 2 mM blood glucose for more than 2 hr) without the presence of iso-EEG, induces scattered neuronal death in the cerebral cortex [12], but not in the hippocampus [13,14]. Yamada et al. also found that moderate hypoglycemia did not result in hippocampal neuronal death. However, they did find a deficit in the ability to induce long term potentiation (LTP) at CA1 synapses [13]. For this reason, we hypothesized that repetitive episodes of moderate hypoglycemia may induce synaptic injury in the hippocampus, and consequently the development of cognitive impairment. In support of this hypothesis, we recently demonstrated that repetitive episodes of moderate hypoglycemia leads to synaptic injury in the dendritic area of hippocampus in the absence of detectable neuronal somatic injuries [14]. The neuronal death resulting from hypoglycemia is not solely a result of energy failure, but rather results from a sequence of events initiated by hypoglycemia/glucose reperfusion. This sequence of events includes release of synaptic glutamate and activation of neuronal glutamate receptors [15-18], the production of reactive (+)-Clopidogrel hydrogen sulfate (Plavix) oxygen species [19,20], accumulation of intracellular zinc[21], activation of poly(ADP-ribose) polymerase-1 [5,22], and mitochondrial (+)-Clopidogrel hydrogen sulfate (Plavix) permeability transition [23-25]. Correction of plasma glucose concentration alone does not interrupt this cell death process [5,22]. During hypoglycemia, conditions that favor the depletion of ATP predominate [26]. Combined glutamate/zinc release and translocation of zinc into postsynaptic neurons induce poly (ADP-ribose) polymerase (PARP) activation after Rabbit Polyclonal to PITX1 hypoglycemia, which results in energy depletion and neurodegeneration. Adding strong support to the deleterious role of zinc-induced-PARP activation in the etiology of hypoglycemia, hypoglycemia-induced hippocampal neuronal death and spatial learning ability impairment were significantly spared by treatment with PARP inhibitors [5] and by zinc chelators [21]. However, the realization of using either PARP inhibitors or zinc chelators as clinically efficacious neuroprotective agents will require further study, both to gain a more precise understanding of their pharmacological effects and to identify efficient delivery methods, as well as to rule out cytotoxicity. Therefore, it is important to identify other means of intervention beyond PARP inhibitors or zinc chelators, that are both non-toxic and deliverable in the clinic quickly. To date, many hypoglycemia experiments have already been performed with normoglycemic (nondiabetic) adult rodents; which means exact medical implications of the studies isn’t readily obvious since moderate hypoglycemia frequently happens in juvenile type 1 diabetes individuals, rather.